Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease

• Published in: Journal of neuroinflammation 2019-04, Vol.16 (1), p.74-13, Article 74
• Main Authors: Dionisio-Santos, Dawling A, Olschowka, John A, O'Banion, M Kerry
• Format: Article
• Language: English
• Subjects: Adaptive immunity; Aging; Alzheimer's disease; Amyloid; Analysis; Animal models; Astrocytes; Brain research; Care and treatment; Chemokines; Cognitive ability; Cytokines; Dementia disorders; Development and progression; Disease prevention; Endothelial cells; Hippocampus; Homeostasis; Immune clearance; Immune system; Inflammation; Innate immunity; Lymphocytes T; Microglia; Monocytes; Neurodegeneration; Nonsteroidal anti-inflammatory drugs; Pathology; Peripheral nervous system; Phenotypes; Physiological aspects; Review; Senile plaques; Studies; Systematic review; Tau protein; Therapeutic applications; Therapeutics; Transgenic animals
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-019-1453-0

Neuroinflammation is considered one of the cardinal features of Alzheimer's disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyloid β causes these cells to acquire an inflammatory phenotype. While these reactive microglia are important to contain and phagocytose amyloid plaques, their activated phenotype impacts CNS homeostasis. In rodent models, increased neuroinflammation promoted by overexpression of proinflammatory cytokines can cause an increase in hyperphosphorylated tau and a decrease in hippocampal function. The peripheral immune system can also play a detrimental or beneficial role in CNS inflammation. Systemic inflammation can increase the risk of developing AD dementia, and chemokines released directly by microglia or indirectly by endothelial cells can attract monocytes and T lymphocytes to the CNS. These peripheral immune cells can aid in amyloid β clearance or modulate microglia responses, depending on the cell type. As such, several groups have targeted the peripheral immune system to modulate chronic neuroinflammation. In this review, we focus on the interplay of immunomodulating factors and cell types that are being investigated as possible therapeutic targets for the treatment or prevention of AD.